Indoco Remedies Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Indoco Remedies Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Growth Efficiency Ratio: Sales grew 9% in 3 years, but profit fell: ₹155 less profit per ₹100 of extra sales. Lower than almost all Healthcare companies in India.
- Cash Cushion Ratio: Debt, after subtracting cash, equals 50% of its market value (net debt). Lower than 97% of Healthcare companies in India.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 0 of 3. Less steady than 94% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
0.6×Over the last 3 years its own operating cash paid for 58% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 79% of Healthcare companies in India.
Cash Locked Ratio
₹33For every ₹100 of sales, ₹33 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹32 tied up three years earlier.
More money tied up than 66% of Healthcare companies in India.
Growth quality
Steadiness Ratio
2/3 · 0/3Sales grew in 2 of the last 3 years; profit grew in 0 of 3.
Less steady than 94% of Healthcare companies in India.
Growth Efficiency Ratio
−₹155Sales grew 9% in 3 years, but profit fell: ₹155 less profit per ₹100 of extra sales.
Lower than almost all Healthcare companies in India.
Asset Productivity Ratio
+9% / +56%In 3 years sales changed by +9% while total assets changed by +56%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
0.4×Debt due within a year is covered 0.4 times by its yearly operating cash.
Lower than 73% of Healthcare companies in India.
Cash Cushion Ratio
−50%Debt, after subtracting cash, equals 50% of its market value (net debt).
Lower than 97% of Healthcare companies in India.
Tangible Assets Ratio
92%Of every ₹100 the company owns, ₹92 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 65% of Healthcare companies in India.
Tangible Net Worth Ratio
79%Of every ₹100 of net worth, ₹79 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 75% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Indoco Remedies Limited owes ₹0.64 for every ₹1 it owns. Indoco Remedies Limited made a loss in each of the last two years.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
705.0Investors pay ₹705.0 for every ₹1 of Indoco Remedies Limited's yearly profit, higher than almost all Healthcare companies in India.
P/B ratio
2.21The share price is 2.21 times Indoco Remedies Limited's book value per share, lower than 84% of Healthcare companies in India.
Market cap
₹2,079 CrThe total market value of all of Indoco Remedies Limited's shares at today's price (share price × number of shares), smaller than 65% of Healthcare companies in India. PosiCap size class: Mini Cap.
Net worth (book value)
₹939 CrWhat Indoco Remedies Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹101.90Net worth divided by the number of shares. The share price of ₹225.60 is 2.2 times this, which is the P/B above.
Return on equity (ROE)
0.3%Indoco Remedies Limited earned 0.3% on its shareholders' money over the last year, lower than 92% of Healthcare companies in India.
Owes vs Owns
0.64×Indoco Remedies Limited owes ₹0.64 for every ₹1 it owns (moderate), higher than 94% of Healthcare companies in India.
Dividend yield
0.09%Indoco Remedies Limited pays 0.09% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in India.
Revenue growth
+9%Revenue rose 9% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Profit growth
LossIndoco Remedies Limited made a loss in each of the last two years.
Profit margin
-5.3%Indoco Remedies Limited lost ₹5 for every ₹100 of revenue.
Interest cover
0.1×Indoco Remedies Limited's operating profit covered its interest costs 0.1 times in the year to Mar 2026.
Cash vs debt
Net debtIndoco Remedies Limited had ₹1,044 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Indoco Remedies Limited's P/E ratio?
Investors pay ₹705.0 for every ₹1 of Indoco Remedies Limited's yearly profit, higher than almost all Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Indoco Remedies Limited: ₹2,079 Cr ÷ ₹939 Cr (31 Mar 2026) = 2.2.
What is Indoco Remedies Limited's return on equity?
Indoco Remedies Limited earned 0.3% on its shareholders' money over the last year, lower than 92% of Healthcare companies in India.
How much does Indoco Remedies Limited owe compared with what it owns?
Indoco Remedies Limited owes ₹0.64 for every ₹1 it owns (moderate), higher than 94% of Healthcare companies in India.
Does Indoco Remedies Limited pay a dividend?
Yes. Indoco Remedies Limited pays 0.09% of its share price as dividends a year, lower than 90% of dividend-paying Healthcare companies in India.
Is Indoco Remedies Limited's revenue growing?
Revenue rose 9% in the year to Mar 2026, and grew 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.